Biocardia Inc (BCDA) Stock Price, Quote & News

Company Profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 226 0120

Fax: 650 631 3731

Website: www.biocardia.com

Address:

320 Soquel Way, Sunnyvale, United States

Dickman777 May. 12 at 3:36 PM

$AEHL got it again pretty cool huh? 🤑🤑🤑 $CNCK lets break that 2.30 $BCDA tiktok tiktok 😎🙌🏼 What a day so far!!

0 · Reply

Dickman777 May. 12 at 2:52 PM

$AEHL are you sick of me yet?? This will make you puke!! Puke money 🤑🤑🤑 Now I’m telling you again there could be 3 PR’s done at $BCDA by the end of May! Load this ticker!! The proof is here! Be wealthy. My friends! $CREG $TDIC $ERNA

0 · Reply

Dickman777 May. 12 at 2:39 PM

$ERNA we were loaded, saw the potential, got paid!! Keep laughing and talking, we are PRINTING!! $BCDA this is what the loading phase looks like here! It is coming it WILL happen! I hope you are there when it does!! $AEHL $BZFD $CREG

0 · Reply

Raycloser May. 12 at 5:10 AM

$BCDA why the earnings call on a Friday after the market closes

0 · Reply

focafoca99 May. 12 at 2:54 AM

$BCDA hosts its Q1 2026 results and corporate update call for May 15.

0 · Reply

Klinsmann May. 11 at 7:18 PM

$BCDA word seems to be slowly spreading. Imagine they present fda approval during the next 2 weeks… Very nice hidden gem, trading at the very low.

1 · Reply

Dickman777 May. 11 at 7:12 PM

$BCDA who else is here, anyone?? Ok, i will tell you who is here and loaded, remember dbr, dabullrunner? Yeah, guess who loaded $TRAW guess who is loaded here?? He is him!! And we just turned green don’t tell me you were not warned!! $POM $MEHA $HAO we are loaded, didn’t front load on you guys either!

0 · Reply

Klinsmann May. 11 at 7:11 PM

$BCDA 👀

0 · Reply

Dickman777 May. 11 at 3:29 PM

$BCDA not much action here today, just like the manipulation at $TRAW friday, they want your shares! I’ll be loading until they get their fill, and send it!!

0 · Reply

Dickman777 May. 11 at 2:12 PM

$BCDA not 1, not 2, but 3 potential PR in this month of May!! Here we go, buy it cheap, load dips, be here for the rips!! Smelling wealthy 🧐 key words, raised NO concerns!! Read the fine print folks you will make money here!! $JZXN $TRAW $MEHA $RXT

0 · Reply

BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026

2026-05-08T18:14:28.000Z - 4 days ago

BioCardia provides update on Helix pre-submission meeting with FDA

2026-04-20T13:09:35.000Z - 22 days ago

BioCardia reports ‘positive’ outcome in consult with Japan’s PMDA for CardiAMP

Apr 20, 2026, 8:00 AM EDT - 23 days ago

BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure

2026-04-02T14:20:13.000Z - 5 weeks ago

BioCardia files request for meeting with FDA to discuss CardiAMP pathway

Mar 24, 2026, 4:30 PM EDT - 7 weeks ago

BioCardia Earnings Call Transcript: Q4 2025

Mar 24, 2026, 4:05 PM EDT - 7 weeks ago

BioCardia Reports 2025 Business Highlights and Financial Results

Mar 19, 2026, 7:47 PM EDT - 7 weeks ago

BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026

2026-03-17T10:05:13.000Z - 2 months ago

BioCardia’s pre-submission package for Helix catheter approved by FDA

2026-03-03T13:42:33.000Z - 2 months ago

BioCardia reports results from Phase III trial for ischemic heart failure

2026-02-10T14:21:02.000Z - 3 months ago

BioCardia files pre-submission for FDA approval of Helix catheter

Feb 10, 2026, 9:15 AM EST - 3 months ago

BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart

2025-12-16T13:10:48.000Z - 5 months ago

BioCardia completed third preliminary clinical consultation with Japan’s PMDA

Dec 16, 2025, 8:00 AM EST - 5 months ago

BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA

2025-12-03T13:16:10.000Z - 5 months ago

BioCardia appoints Slosman to its Board of Directors

NSPR

Dec 1, 2025, 8:30 AM EST - 5 months ago

BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

2025-11-24T13:41:01.000Z - 6 months ago

BioCardia appoints Farhan Shahab as VP, quality

Nov 24, 2025, 8:15 AM EST - 6 months ago

BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

Nov 12, 2025, 4:40 PM EST - 6 months ago

BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

Nov 12, 2025, 4:30 PM EST - 6 months ago

BioCardia Earnings Call Transcript: Q3 2025

2025-11-10T13:47:11.000Z - 6 months ago

BioCardia first patient enrolled at Henry Ford Health for Phase 3 CardiAMP

Nov 5, 2025, 7:29 PM EST - 6 months ago

BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

2025-10-30T12:26:50.000Z - 6 months ago

BioCardia announces patient enrolled at Wisconsin School for CardiAMP trial

2025-10-02T12:10:31.000Z - 7 months ago

BioCardia regains compliance with Nasdaq listing requirements

Oct 2, 2025, 8:00 AM EDT - 7 months ago

BioCardia Regains Compliance with Nasdaq Listing Requirements

2025-09-22T12:05:28.000Z - 8 months ago

BioCardia announces preliminary consultation with Japan PDMA on CardiAMP results

2025-09-18T13:25:16.000Z - 8 months ago

BioCardia prices 4.8M shares at $1.25 in public offering

Sep 18, 2025, 9:15 AM EDT - 8 months ago

BioCardia Announces Pricing of Up To $12 Million Public Offering

2025-09-18T11:07:02.000Z - 8 months ago

BioCardia announces CardiAMP Cell Therapy results

Sep 18, 2025, 7:00 AM EDT - 8 months ago

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

2025-09-16T13:10:38.000Z - 8 months ago

BioCardia files to sell 2.8M shares of common stock, warrants

Sep 4, 2025, 9:00 AM EDT - 8 months ago

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

2025-08-13T12:20:49.000Z - 9 months ago

BioCardia, CART-Tech enter exclusive agreement for Heart3D Fusion Imaging

Aug 11, 2025, 4:30 PM EDT - 9 months ago

BioCardia Earnings Call Transcript: Q2 2025

2025-08-11T13:21:22.000Z - 9 months ago

BioCardia reports Q2 EPS (40c) vs. (88c) last year

2025-08-11T13:21:09.000Z - 9 months ago

BioCardia sees cash runway into October

Aug 11, 2025, 9:15 AM EDT - 9 months ago

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

Aug 6, 2025, 3:18 PM EDT - 9 months ago

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

Aug 4, 2025, 6:00 AM EDT - 10 months ago

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

May 21, 2025, 3:40 PM EDT - 1 year ago

BioCardia Transcript: A.G.P. Virtual Annual Healthcare Company Showcase

May 21, 2025, 8:30 AM EDT - 1 year ago

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings Call Transcript: Q1 2025

May 14, 2025, 4:05 PM EDT - 1 year ago

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

May 9, 2025, 4:28 PM EDT - 1 year ago

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

Apr 11, 2025, 9:15 AM EDT - 1 year ago

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Mar 31, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings Call Transcript: Q4 2024

Mar 31, 2025, 1:39 PM EDT - 1 year ago

BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

Mar 26, 2025, 4:30 PM EDT - 1 year ago

BioCardia Reports 2024 Business Highlights and Financial Results

Mar 21, 2025, 8:30 AM EDT - 1 year ago

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

Mar 10, 2025, 9:15 AM EDT - 1 year ago

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

Feb 27, 2025, 9:15 AM EST - 1 year ago

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

Feb 13, 2025, 8:30 AM EST - 1 year ago

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

Jan 27, 2025, 9:15 AM EST - 1 year ago

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

Dec 4, 2024, 8:30 AM EST - 1 year ago

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

Nov 13, 2024, 4:30 PM EST - 1 year ago

BioCardia Earnings Call Transcript: Q3 2024

Sep 18, 2024, 8:30 AM EDT - 1 year ago

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

Sep 9, 2024, 4:05 PM EDT - 1 year ago

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Aug 29, 2024, 8:30 AM EDT - 1 year ago

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

Aug 21, 2024, 7:00 AM EDT - 1 year ago

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

Aug 13, 2024, 4:30 PM EDT - 1 year ago

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

Aug 13, 2024, 4:30 PM EDT - 1 year ago

BioCardia Earnings Call Transcript: Q2 2024

Jul 17, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

Jun 7, 2024, 7:00 AM EDT - 2 years ago

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

May 21, 2024, 5:00 PM EDT - 2 years ago

BioCardia Announces Reverse Stock Split

May 14, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings Call Transcript: Q1 2024

May 14, 2024, 4:02 PM EDT - 2 years ago

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

May 9, 2024, 7:00 AM EDT - 2 years ago

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

May 1, 2024, 7:00 AM EDT - 2 years ago

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

Apr 30, 2024, 3:00 PM EDT - 2 years ago

BioCardia Transcript: Status Update

Apr 25, 2024, 9:00 AM EDT - 2 years ago

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

Mar 27, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings Call Transcript: Q4 2023

Mar 27, 2024, 4:00 PM EDT - 2 years ago

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

Mar 20, 2024, 7:00 AM EDT - 2 years ago

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

Mar 13, 2024, 7:00 AM EDT - 2 years ago

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

Mar 12, 2024, 7:00 AM EDT - 2 years ago

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Mar 4, 2024, 8:00 AM EST - 2 years ago

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

Feb 8, 2024, 7:00 AM EST - 2 years ago

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

Jan 31, 2024, 7:00 AM EST - 2 years ago

BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference

Jan 3, 2024, 7:00 AM EST - 2 years ago

BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

Dec 19, 2023, 7:00 AM EST - 2 years ago

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

Dickman777 May. 12 at 3:36 PM

$AEHL got it again pretty cool huh? 🤑🤑🤑 $CNCK lets break that 2.30 $BCDA tiktok tiktok 😎🙌🏼 What a day so far!!

0 · Reply

Dickman777 May. 12 at 2:52 PM

0 · Reply

Dickman777 May. 12 at 2:39 PM

0 · Reply

Raycloser May. 12 at 5:10 AM

$BCDA why the earnings call on a Friday after the market closes

0 · Reply

focafoca99 May. 12 at 2:54 AM

$BCDA hosts its Q1 2026 results and corporate update call for May 15.

0 · Reply

Klinsmann May. 11 at 7:18 PM

$BCDA word seems to be slowly spreading. Imagine they present fda approval during the next 2 weeks… Very nice hidden gem, trading at the very low.

1 · Reply

Dickman777 May. 11 at 7:12 PM

0 · Reply

Klinsmann May. 11 at 7:11 PM

$BCDA 👀

0 · Reply

Dickman777 May. 11 at 3:29 PM

$BCDA not much action here today, just like the manipulation at $TRAW friday, they want your shares! I’ll be loading until they get their fill, and send it!!

0 · Reply

Dickman777 May. 11 at 2:12 PM

0 · Reply

Jusme May. 11 at 2:10 PM

$BCDA Available shares to short dropped dramatically from Friday.

0 · Reply

Dickman777 May. 11 at 1:46 PM

$TRAW you were not late this time i said it below!! $BCDA it will happen under 1.20 makes zero sense $YYGH in will load all the dips here too!! $JZXN needs 1.40 for more!!

1 · Reply

brptrader May. 11 at 1:33 PM

$BCDA who buys 7 shares at a time???

0 · Reply

sk7777777 May. 9 at 8:59 PM

$BCDA

0 · Reply

Jusme May. 9 at 1:48 AM

$BCDA Guessing that warrants were executed as a means of fulfilling company cash infusion reqs… but we’ll see more insights next week.

2 · Reply

brptrader May. 8 at 9:00 PM

$BCDA we will see what Monday brings

0 · Reply

Lstreak May. 8 at 8:06 PM

$BCDA Nice volume today!!

0 · Reply

Dickman777 May. 8 at 7:57 PM

$BCDA i told you…. Something was holding this back!!

1 · Reply

rockytoday May. 8 at 7:55 PM

$BCDA will fly after hours

0 · Reply

chris_stocks May. 8 at 6:37 PM

$BCDA I said it before and I'll say it again. Whenever the stock gets good news the stock price goes down.

0 · Reply

Dickman777 May. 8 at 6:04 PM

$BCDA still playing the MM’s games here too!! Under 1.20 with this news is criminal! You’ll see

0 · Reply

11lp May. 8 at 4:40 PM

$BCDA they take full advantage of having a public stock and it’s by screwing you

0 · Reply

Market Cap	12.14M
Revenue (ttm)	0.00
Net Income (ttm)	-8.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	109,100
Avg Vol	169,316
Day's Range	N/A - N/A
Shares Out	10.94M
Stochastic %K	59%
Beta	0.56
Analysts	Sell
Price Target	$15.50